Cargando…
布格替尼治疗ALK阳性NSCLC患者期间相关早发性肺事件及其管理策略
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in signal dysregulation in kinase domain. As a new generation of potent ALK tyrosine kinase inhibitors (TKIs), Brigatinib was approved in China in March 2022 a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186256/ https://www.ncbi.nlm.nih.gov/pubmed/37183643 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.12 |